Key points are not available for this paper at this time.
The central biomedical challenge for human exploration is not simply how far spacecraft can travel but whether human physiology can adapt safely to prolonged life beyond Earth.Spaceflight provides a unique testbed for defining the limits of physiological adaptation and resilience.The human body, adapted to Earth's gravitational environment, must respond simultaneously to microgravity or partial gravity, ionising radiation, altered atmospheric composition, circadian disruption and confinement.Determining when these responses progress from adaptation to deconditioning, disease and impaired operational performance is essential for crew health and mission success.The resulting insights also inform ageing, physical inactivity, critical illness, musculoskeletal and cardiovascular disease, and healthcare delivery in remote or resource-limited environments.This is a particularly timely period for space physiology.On 6 April 2026, Artemis II conducted the first crewed lunar flyby in >50 years, with subsequent Artemis missions intended to support sustained human activity on and around the Moon and prepare for future missions to Mars (National Aeronautics Bailey et al., 2025).Deeper longitudinal phenotyping of the exposome-integrome interaction is therefore needed to determine how combined stressors modify individual risk and to guide personalised countermeasure selection.Although >30 health risks have been associated with exploration-class missions, the additive, antagonistic and non-linear effects of combined exposures remain poorly characterised (Bailey, 2025; Bailey et al., 2025).
Damian M. Bailey (2026) studied this question.